Trending archive
Every article that has appeared in Trending stays here. Search by title, journal, author or PMID, and narrow by date.
33 articles
October 202611
Novel Imaging Techniques Prior to Surgical Management of Invasive Bladder Cancer: A Systematic Review.
This PRISMA-guided systematic review assessed novel imaging for detecting muscle invasion and nodal disease before surgical management of invasive bladder cancer. It included 33 studies encompassing 4,689 patients.
Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).
This multicenter phase I dose-escalation and dose-expansion study evaluated [177Lu]lutetium-dotatate plus oral triapine in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.
A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti-PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer.
This phase I dose-escalation and expansion study evaluated fractionated and repeated-cycle 225Ac-J591 in patients with progressive metastatic prostate cancer resistant to androgen pathway modulation.
Volumetric discordance between ¹⁸F-FET-PET/MRI and MRI-based radiotherapy target volumes in high-grade glioma: a prospective pilot study (FETSMaRT).
This prospective pilot study enrolled 30 patients with WHO grade 3 or 4 high-grade glioma receiving postoperative radiotherapy.
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.
This individual participant data meta-analysis examined amyloid PET scans from 49,227 participants across 53 studies to establish Centiloid positivity cutoffs for Alzheimer disease diagnosis.
Clinical Trial Protocol for LPS-Boost: Intensified [ 177 Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
This multicenter, open-label phase 2 trial investigates an intensified treatment schedule of [177Lu]Lu-PSMA-617 for 45 patients with metastatic castration-resistant prostate cancer (mCRPC) and low PSMA expression.
Tumor and Organ Dose Estimates from 177 Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.
The RESIST-PC Phase 2 trial assessed dosimetry of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. A total of 48 patients were analyzed, receiving either 6.0 or 7.4 GBq per cycle.
A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [ 177 Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).
The OPTIMAL-PSMA study is a Phase 2, open-label, randomized controlled trial evaluating the safety and efficacy of a dose-intensified regimen of [177Lu]Lu-PSMA-597 versus standard dosing in 120 patients with metastatic…
First-in-Human, Open-label, Single-Arm Phase I Study of [211At] meta-Astatobenzylguanidine in Patients with Pheochromocytoma or Paraganglioma.
This first-in-human, open-label, single-arm Phase I study evaluated the safety and pharmacokinetics of 211At-meta-astatobenzylguanidine (211At-MABG) in 10 patients with unresectable or metastatic pheochromocytomas or…
Follow-Up 18F-Fluorodeoxyglucose Positron Emission Tomography in Treated Patients With Giant Cell Arteritis: A Systematic Review and Metaanalysis.
This systematic review and meta-analysis evaluated the use of 18F-fluorodeoxyglucose (FDG) PET to monitor disease activity in patients with large-vessel giant cell arteritis (LV-GCA) who showed clinical improvement…
[18F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging.
[18F]RCCB6 PET/CT was evaluated in a single-center phase II trial for detecting metastases in clear-cell renal cell carcinoma (ccRCC).
September 20268
First systematic mapping of non-target [68Ga]Ga-DOTANOC uptake across anatomical sites and etiologies.
This systematic review analyzed 76 studies involving 542 patients to map non-target [68Ga]Ga-DOTANOC uptake across various anatomical sites and etiologies.
Evaluating the Clinical Utility of TSPO-PET in MS and the Influence of Methodological Heterogeneity: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis evaluated TSPO-PET imaging in multiple sclerosis (MS) patients compared to healthy controls.
Clinical utility of DaTscan in clinically uncertain parkinsonian syndromes: a systematic review and meta‑analysis.
This systematic review and meta-analysis assessed how often DaTscan (123I-ioflupane SPECT) was followed by a diagnostic change in patients with clinically uncertain parkinsonian syndromes.
Dosimetric and therapeutic effectiveness of high-dose-rate radionuclide sources in breast cancer brachytherapy: A systematic review.
This systematic review compared dosimetric properties and therapeutic evidence for ¹⁹²Ir, ⁶⁰Co, and ¹⁶⁹Yb in high-dose-rate breast cancer brachytherapy.
Brain serotonin transporter remains stable across seasons: A Bayesian and frequentist meta-analysis.
This meta-analysis examined seasonal variations in brain serotonin transporter (SERT) availability in healthy individuals using neuroimaging studies.
Validation of the newly introduced Deauville score 5a for patients treated for advanced-stage classic Hodgkin lymphoma.
This randomized controlled trial evaluated the prognostic value of the newly defined Deauville score 5a in patients with advanced-stage classical Hodgkin lymphoma (AS-cHL) after two cycles of treatment.
Bone metastases in lung carcinoids: current challenges in diagnosis and treatment -A systematic review of an unexplored issue.
This systematic review examined bone metastases (BMs) in lung carcinoid patients, revealing an incidence of 17.2%. The study highlighted the challenges in diagnosis and treatment, noting that BMs were predominantly…
Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.
The Phase I LuMIERE trial evaluated the safety of [177Lu]Lu-FAP-2286 in 27 heavily pretreated patients with advanced solid tumors.
August 20262
A Novel Protocol for Pre-Treatment Diagnostic 131 I Scan Within 24 Hours Post-Second rhTSH Administration to Guide Radioiodine Therapy in Differentiated Thyroid Cancer.
This single-center, prospective clinical trial evaluated the feasibility of performing a diagnostic 131 I whole-body scan (Dx-WBS) within 24 hours after the second rhTSH injection in patients with differentiated thyroid…
From static to dynamic SPECT/CT: A systematic review of clinical applications and perspectives.
This systematic review evaluates the clinical applications of dynamic SPECT/CT across various organ systems, particularly in cardiology and nephrology.
July 20263
Pre-therapeutic PSMA PET Imaging Biomarkers Demonstrate Prognostic Value in Patients Undergoing [ 177 Lu]Lu-PSMA Therapy: A Systematic Review and Meta-analysis.
This systematic review and meta-analysis evaluated the prognostic value of pre-therapeutic PSMA PET imaging biomarkers in 2993 patients undergoing [177 Lu]Lu-PSMA therapy for metastatic castration-resistant prostate…
[ 18 F]FDG PET/MRI for axillary staging in node positive breast cancer patients receiving primary systemic therapy. A prospective single arm trial.
[18F]FDG PET/MRI was evaluated for axillary staging in node-positive breast cancer patients undergoing primary systemic therapy in a prospective single-arm trial.
Comparative diagnostic performance of [ 18 F] flurpiridaz PET and SPECT myocardial perfusion imaging (MPI): a systematic review and meta-analysis.
[¹⁸F]flurpiridaz PET was compared to SPECT myocardial perfusion imaging (MPI) for diagnosing coronary artery disease (CAD) in a systematic review and meta-analysis of 3 trials involving 1476 patients.
Stay updated for free
Get the 3 most interesting publications in one specialty each week.
Weekly email. Unsubscribe anytime.
Want this personalized?
Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.
- Your specialties
- Your filters and thresholds
- Clinical Research + Case Reports, tuned separately
- Automatic weekly delivery
- Audio and text
Prefer listening? Personalized audio digests are available with Pro.